Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study

Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Blood (Impact Factor: 10.43). 06/2008; 111(12):5515-23. DOI: 10.1182/blood-2007-10-117150
Source: PubMed

ABSTRACT Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for late effects of cancer therapy. Five-year ALL survivors (< 21 years at diagnosis; n = 5760 eligible, 4151 participants), diagnosed from 1970 to 1986 were compared with the general population and a sibling cohort (n = 3899). Cumulative mortality of 5760 5-year survivors was 13% at 25 years from diagnosis. Recurrent ALL (n = 483) and second neoplasms (SNs; n = 89) were the major causes of death. Among 185 survivors, 199 SNs occurred, 53% in the CNS. Survivors reported more multiple chronic medical conditions (CMCs; odds ratio [OR], 2.8; 95% CI, 2.4-3.2) and severe or life-threatening CMCs (OR, 3.6; 95% CI, 3.0-4.5) than siblings. Cumulative incidence of severe CMCs, including death, 25 years from diagnosis was 21.3% (95% CI, 18.2-24.4; 23.3% [95% CI, 19.4-27.2] and 13.4% [95% CI, 8.4-18.4] for irradiated and nonirradiated survivors, respectively). Survivors reported more adverse general and mental health, functional impairment, and activity limitations compared with siblings (P < .001). Rates of marriage, college graduation, employment, and health insurance were all lower compared with sibling controls (P < .001). Long-term survivors of childhood ALL exhibit excess mortality and morbidity. Survivors who received radiation therapy as part of their treatment or had a leukemia relapse are at greatest risk for adverse outcomes.

Download full-text


Available from: Wendy Leisenring, Aug 24, 2015
  • Source
    • "[3] [4] [31] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Childhood cancer incidence in Suriname (South-America) was estimated using secondary data from 1980 to 2008, and these findings were stratified according to gender; age groups < 1, 1-4, 5-14, and 15-19 years; and the largest ethnic groups (Hindustanis, Maroons, Creoles, and Javanese). Data were expressed as total numbers, proportions, average yearly numbers, and/or crude incidence rates per 1,000,000 population per year. There were 290 malignancies in the period covered, i.e., about 10 new cases per year or 24 per 1,000,000 per year. The average yearly number of overall cancer increased from approximately 1 every two years in newborns to 3-4 per year in adolescents and young adults. Thirty to 35% of patients were Hindustani or Creole; the proportions of Javanese and Maroons patients were about twice and five times, respectively, lower. Leukemias and lymphomas comprised almost half of cases, each occurring 2 to 3 times per year. Bone tumors, soft-tissue sarcomas, and carcinomas were the most common non-hematological malignancies, occurring once or twice per year. Central nervous system tumors, neuroblastoma, retinoblastoma, renal tumors, primary hepatic tumors, and germ cell tumors were exceedingly rare. In conclusion, childhood cancer incidence in Suriname was relatively low; the individual histiotypes displayed an unusual ranking; and there were differences in the sex, age, and ethnic distribution of overall cancer as well as certain histiotypes. However, these observations might be biased by the use of crude rates, and underdiagnosis and incomplete registration of cases due to the absence of specialized (pediatric) cancer facilities in the country.
    The Open Epidemiology Journal 07/2014; 7(1):27-36. DOI:10.2174/1874297120140701004
  • Source
    • "Childhood ALL (acute lymphoblastic leukaemia) is cured in ,80– 90% of the patients, but a significant number of survivors suffer from chemotherapy-induced side effects (Mody et al., 2008). These can appear during treatment or become clinically evident years after therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anthracyclines are potent cytostatic drugs, the correct dosage being critical to avoid possible cardiac side effects. ABCC1 [ATP-binding cassette, sub-family C, member 1; also denoted as MRP1 (multidrug resistance-associated protein 1)] is expressed in the heart and takes part in the detoxification and protection of cells from the toxic effects of xenobiotics, including anthracyclines. Our objective was to search for associations between LV (left ventricular) function and single-nucleotide polymorphisms of the ABCC1 gene in children receiving anthracycline chemotherapy. Data of 235 paediatric patients with acute lymphoblastic leukaemia was analysed. Patients were followed-up by echocardiography (median follow-up 6.3 years). Nine polymorphisms in the ABCC1 gene were genotyped. The ABCC1 rs3743527TT genotype and rs3743527TT–rs246221TC/TT genotype combination were associated with lower LVFS (left ventricular fractional shortening) after chemotherapy. The results suggest that genetic variants in the ABCC1 gene influence anthracycline-induced LV dysfunction.
    Cell Biology International 09/2011; 36(1):79-86. DOI:10.1042/CBI20110264 · 1.64 Impact Factor
  • Source
    • "Individuals with a history of childhood cancer have 10–20 fold greater risk of developing a secondary malignant neoplasm within the first 20 years after treatment [54] turning therapy-related neoplasias a worldwide problem of major proportions [55] [56]. Between 10% and 20% of acute leukemia patients reported in various series have developed a secondary cancer following previous therapy, and considering cured ALL patients, a greater frequency of neoplasias has been observed when compared to normal individuals [8] [57] [58]. None of our patients developed a secondary cancer over 5 years of clinical follow-up. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Contemporary anticancer therapies have largely improved the outcome for children with cancer, especially for Acute Lymphoblastic Leukemia (ALL). Actually, between 78% and 85% of patients achieve complete remission and are alive after 5 years of therapy completion. However, as cure rates increase, new concerns about the late effects of genotoxic treatment emerge, being the risk of developing secondary neoplasias, the most serious life-threatening rising problem. In the present paper, we describe and review the cytogenetic findings in peripheral lymphocytes from ALL survivors, and discuss aspects associated to the occurrence of increased chromosome rearrangements in this growing cohort.
    BioMed Research International 01/2011; 2011. DOI:10.1155/2011/230481 · 2.71 Impact Factor
Show more